# CKD-391 Pharmacokinetic Study

> **NCT02461004** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CKD-391
- **DRUG:** Atrovastatin and Ezetimibe combination therapy

## Key facts

- **NCT ID:** NCT02461004
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461004, "CKD-391 Pharmacokinetic Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02461004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*